- Home
- TWFG vs KURA Comparison
TWFG vs KURA Comparison
Compare TWFG & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWFG
- KURA
- Stock Information
- Founded
- TWFG 2001
- KURA 2014
- Country
- TWFG United States
- KURA United States
- Employees
- TWFG N/A
- KURA N/A
- Industry
- TWFG
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TWFG
- KURA Health Care
- Exchange
- TWFG NYSE
- KURA Nasdaq
- Market Cap
- TWFG 521.8M
- KURA 561.9M
- IPO Year
- TWFG 2024
- KURA N/A
- Fundamental
- Price
- TWFG $33.19
- KURA $6.44
- Analyst Decision
- TWFG Buy
- KURA Strong Buy
- Analyst Count
- TWFG 8
- KURA 12
- Target Price
- TWFG $35.57
- KURA $24.50
- AVG Volume (30 Days)
- TWFG 122.5K
- KURA 1.4M
- Earning Date
- TWFG 08-26-2025
- KURA 08-07-2025
- Dividend Yield
- TWFG N/A
- KURA N/A
- EPS Growth
- TWFG N/A
- KURA N/A
- EPS
- TWFG N/A
- KURA N/A
- Revenue
- TWFG $211,440,000.00
- KURA $67,991,000.00
- Revenue This Year
- TWFG $23.90
- KURA $125.04
- Revenue Next Year
- TWFG $22.60
- KURA $83.75
- P/E Ratio
- TWFG N/A
- KURA N/A
- Revenue Growth
- TWFG 18.57
- KURA N/A
- 52 Week Low
- TWFG $21.31
- KURA $5.41
- 52 Week High
- TWFG $36.85
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- TWFG N/A
- KURA 59.02
- Support Level
- TWFG N/A
- KURA $5.65
- Resistance Level
- TWFG N/A
- KURA $6.46
- Average True Range (ATR)
- TWFG 0.00
- KURA 0.26
- MACD
- TWFG 0.00
- KURA 0.07
- Stochastic Oscillator
- TWFG 0.00
- KURA 97.73
About TWFG TWFG INC
TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.